SCHEDULE: Gilead Boosts Stake in Assembly Bio to 29%

Gilead Sciences, Inc. increased its beneficial ownership in Assembly Biosciences, Inc. to 29% through a $45 million investment in common stock and warrants.

Summary

• Gilead Sciences, Inc. (Gilead) has increased its beneficial ownership in Assembly Biosciences, Inc. (Issuer) to 29% of the outstanding Common Stock.
• This increase is based on 15,560,009 shares of Common Stock outstanding following the Issuer's public offering completed on August 11, 2025.
• Gilead acquired 2,295,920 shares of Common Stock, a Series A warrant for 1,147,960 shares, and a Series B warrant for 1,147,960 shares.
• The total purchase price for this transaction was approximately $45 million, funded by Gilead's available cash resources.
• The combined purchase price was $19.60 per share of Common Stock and accompanying one half of one Series A Warrant and one half of one Series B Warrant.
• Gilead now beneficially owns 4,505,391 shares of Assembly Biosciences Common Stock.
• The Series A Warrant is immediately exercisable at $21.60 per share and expires by August 11, 2030, or 30 days after the Issuer completes Phase 2 enrollment for ABI-5366.
• The Series B Warrant is exercisable from November 15, 2026, at $21.60 per share and expires December 31, 2026, unless the Issuer secures $75 million in non-dilutive capital from a collaboration before November 15, 2026.
• Gilead also holds a 2024 Warrant for 179,500 shares.
• Warrants are subject to a 19.99% beneficial ownership limitation, meaning the underlying shares are not currently counted in the 29% beneficial ownership.

Sentiment

Score: 8

Explanation: The filing indicates a significant strategic investment by a major pharmaceutical company into a smaller biotech firm, providing substantial capital and validation. While there is dilution, the overall financial strengthening and vote of confidence are highly positive for Assembly Biosciences.

Positives

• Assembly Biosciences received approximately $45 million in capital from a significant pharmaceutical company, Gilead Sciences, strengthening its financial position.
• The investment by Gilead, a major industry player, signals confidence in Assembly Biosciences' strategic direction and pipeline, particularly the ABI-5366 program.
• The Series B Warrant includes a condition that could lead to its termination if Assembly Biosciences secures $75 million in non-dilutive capital from a collaboration, incentivizing strategic partnerships.

Negatives

• The issuance of new shares and warrants to Gilead results in dilution for existing shareholders.
• The exercise prices of the warrants ($21.60) are above the initial combined purchase price ($19.60), indicating potential future dilution if exercised.
• The Series B Warrant's termination condition tied to a $75 million non-dilutive capital raise suggests a potential need for further significant funding.

Risks

• Dilution Risk: Future exercise of the Series A, Series B, and 2024 Warrants by Gilead would lead to further dilution of existing shareholders' ownership.
• Warrant Expiration/Termination Risk: The Series A Warrant's expiration is tied to clinical trial progress, and the Series B Warrant's termination is tied to securing non-dilutive capital, introducing uncertainty regarding their future impact.
• Beneficial Ownership Limitation: Gilead's ability to exercise warrants is capped at 19.99% beneficial ownership, which could limit the immediate capital infusion from warrant exercises if Gilead's stake approaches this threshold.

Future Outlook

The Series A Warrant's expiration is linked to the completion of enrollment for Assembly Biosciences' Phase 2 clinical study evaluating ABI-5366 vs. valacyclovir, indicating a future milestone for the company's pipeline. The Series B Warrant's potential termination is contingent on Assembly Biosciences securing at least $75 million in non-dilutive capital from a collaboration agreement by November 15, 2026, suggesting a strategic focus on future partnerships and funding.

Industry Context

This investment by Gilead Sciences, a global biopharmaceutical company, in Assembly Biosciences, a clinical-stage biotechnology firm, highlights a common trend of larger pharmaceutical companies investing in or partnering with smaller biotech firms to access innovative pipelines and technologies. Such strategic investments can provide crucial funding for drug development while offering larger companies potential future assets or market access.

Comparison to Industry Standards

• Strategic investments by large pharmaceutical companies into smaller biotech firms are a common industry practice, often seen with companies like Pfizer investing in early-stage oncology firms or Johnson & Johnson partnering with gene therapy startups. This provides capital to the smaller entity and pipeline access to the larger.
• The 29% stake acquired by Gilead is a significant minority interest, similar to investments seen in other biotech collaborations, such as Sanofi's investment in Regeneron Pharmaceuticals, which evolved into a long-standing partnership.
• The use of warrants with specific exercise conditions, including those tied to clinical trial milestones (like Assembly Biosciences' ABI-5366 Phase 2 enrollment) or non-dilutive financing, is a standard mechanism in biotech funding to align investor interests with company progress and future funding needs.
• The $45 million capital infusion is substantial for a clinical-stage biotech company, comparable to Series B or C funding rounds for companies at a similar development stage, providing runway for ongoing clinical programs.

Related Party Transactions

• The purchase of shares and warrants by Gilead Sciences, Inc. from Assembly Biosciences, Inc. constitutes a related party transaction, as Gilead is now a significant beneficial owner (29%) of Assembly Biosciences.

Stakeholder Impact

• Shareholders: Experience dilution from the issuance of new shares and potential future dilution from warrant exercises, but benefit from the strengthened financial position and strategic validation by Gilead.
• Employees: Increased financial stability may provide greater job security and resources for ongoing research and development.
• Customers/Patients: Potential for accelerated development of ABI-5366 and other pipeline assets due to increased funding, potentially leading to new treatment options.
• Creditors: Improved financial health and backing from a major industry player could enhance creditworthiness.

Next Steps

• Assembly Biosciences to continue its Phase 2 clinical study evaluating ABI-5366 vs. valacyclovir, with enrollment completion impacting the Series A Warrant's expiration.
• Assembly Biosciences may seek to secure at least $75 million in non-dilutive capital from a collaboration agreement by November 15, 2026, which would terminate the Series B Warrant.
• Gilead Sciences may exercise its Series A and Series B Warrants, subject to beneficial ownership limitations and exercise conditions.

Key Dates

Recommendation

The significant investment of $45 million by Gilead Sciences, a leading biopharmaceutical company, into Assembly Biosciences, coupled with Gilead increasing its stake to 29%, represents a strong vote of confidence in Assembly Biosciences' pipeline and strategic direction. This capital infusion provides crucial funding for ongoing clinical programs, particularly ABI-5366, and validates the company's potential. While there is some dilution, the strategic backing and financial stability provided by Gilead outweigh this, making Assembly Biosciences a compelling investment opportunity for long-term growth.

Keywords

Gilead Sciences, Assembly Biosciences, Equity Investment, Warrants, Biotechnology, Pharmaceuticals, SEC Filing, Schedule 13D, Capital Raise, Strategic Investment, ABI-5366